AKT1 and melanoma: Selumetinib has also been associated with other Akt/mTOR inhibitors (MK-2206, rapamycin or AKTi), as described by many groups that confirmed a reduction in cell viability, the blockade of cell cycle progression and concomitant enhanced apoptosis in different melanoma models (human, murine and canine) (34,45,61–63).